Related Experiment Video
Updated: Jul 21, 2025
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment
Julian S Rechberger1,2, Stephanie A Toll3, Wouter J F Vanbilloen1,4
1Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Abstract:
Medulloblastoma is the most common malignant brain tumor in children. Over the last few decades, significant progress has been made in revealing the key molecular underpinnings of this disease, leading to the identification of distinct molecular subgroups with different clinical outcomes. In this review, we provide an update on the molecular landscape of medulloblastoma and treatment strategies. We discuss the four main molecular subgroups (WNT-activated, SHH-activated, and non-WNT/non-SHH groups 3 and 4), highlighting the key genetic alterations and signaling pathways associated with each entity. Furthermore, we explore the emerging role of epigenetic regulation in medulloblastoma and the mechanism of resistance to therapy. We also delve into the latest developments in targeted therapies and immunotherapies. Continuing collaborative efforts are needed to further unravel the complex molecular mechanisms and profile optimal treatment for this devastating disease.
Insights
This review updates on medulloblastoma, the most common pediatric brain cancer. It details molecular subgroups, epigenetic roles, and advances in targeted and immunotherapies for improved treatment.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Molecular Biology
Background:
- Medulloblastoma is the most common malignant pediatric brain tumor.
- Advances in molecular profiling have identified distinct subgroups with varying clinical outcomes.
Purpose of the Study:
- To provide an updated review of the molecular landscape of medulloblastoma.
- To discuss current and emerging treatment strategies based on molecular subgroups.
Main Methods:
- Literature review of medulloblastoma molecular subgroups.
- Analysis of genetic alterations and signaling pathways.
- Exploration of epigenetic regulation and therapeutic resistance.
Main Results:
- Identification of four main molecular subgroups: WNT-activated, SHH-activated, Group 3, and Group 4.
- Highlighting key genetic drivers and pathway dysregulation within each subgroup.
- Discussing the role of epigenetics and mechanisms of therapeutic resistance.
Conclusions:
- Molecular subgrouping is crucial for understanding medulloblastoma.
- Targeted therapies and immunotherapies show promise.
- Continued research and collaboration are essential for optimizing treatment.
More Related Videos
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...